264254-84-4

Basic information

• Product Name: 2’-carboxybenzoyl-7-(N-carboxybenzoyl-β-alanyl)paclitaxel
• Synonyms: 2’-carboxybenzoyl-7-(N-carboxybenzoyl-β-alanyl)paclitaxel
• CAS NO: 264254-84-4
• Molecular Weight: 1193.27
• Mol File: 264254-84-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2’-carboxybenzoyl-7-(N-carboxybenzoyl-β-alanyl)paclitaxel(CAS DataBase Reference)
• NIST Chemistry Reference: 2’-carboxybenzoyl-7-(N-carboxybenzoyl-β-alanyl)paclitaxel(264254-84-4)
• EPA Substance Registry System: 2’-carboxybenzoyl-7-(N-carboxybenzoyl-β-alanyl)paclitaxel(264254-84-4)

Safety Data

• Hazardous Substances Data: 264254-84-4(Hazardous Substances Data)

Upstream product

• 33069-62-4 taxol 
• 501-53-1 benzyl chloroformate 
• 2304-94-1 3-(benzyloxycarbonylamino)propanoic acid 
• 148930-30-7 2’-carboxybenzoylpaclitaxel 

Downstream Products

• 153985-01-4 7-(β-alanyl)paclitaxel 

Relevant articles and documents

Synthesis and biological evaluation of a biotinylated paclitaxel with an extra-long chain spacer arm

A biotinylated paclitaxel derivative with an extra-long chain (LC-LC-biotin) spacer arm was synthesized using an improved synthetic reaction sequence. The biotinylated paclitaxel analogue retained excellent microtubule stabilizing activity in vitro. Furth

Antitumor agents. 256. Conjugation of paclitaxel with other antitumor agents: Evaluation of novel conjugates as cytotoxic agents

Sixteen different taxoid conjugates were prepared by linking various anticancer compounds, including camptothecin (CPT), epipodophyllotoxin (EP), colchicine (COL), and glycyrrhetinic acid (GA), at the 2′- or 7-position on paclitaxel (TXL, 1) through an ester, imine, amine, or amide bond. Newly synthesized conjugates were evaluated for cytotoxic activity against replication of several human tumor cell lines. Among them, TXL-CPT conjugates, 8-10, were more potent than TXL itself against the human prostate carcinoma cell line PC-3 (ED50 = 14.8, 3.1, 19.4 nM compared with 55.5 nM), and conjugate 10 was also 8-fold more active than TXL against the LN-CAP prostate cancer cell line. These compounds also possessed anti-angiogenesis ability as well as lower inhibitory effects against a normal cell line (MRC-5). Thus, conjugates 8-10 are possible antitumor drug candidates, particularly for prostate cancer.